StageZero Life Sciences, Ltd. SZLS SZLSF has partnered with DiagnoseAtHome, a multichannel health technology company specializing in at-home health and laboratory testing solutions.
What Happened: Through the partnership, StageZero will make its multi-cancer blood test, Aristotle, available to DiagnoseAtHome's patients in Canada and the U.S.
Built on StageZero's proprietary mRNA gene expression technology platform, Aristotle is a next-generation test that simultaneously screens for multiple cancers from a single blood sample.
Why It's Important: DiagnoseAtHome offers accessible at-home health and lab testing solutions, allowing businesses, organizations, and healthcare providers to provide safe, accurate, and discreet lab testing to patients as an alternative to in-person laboratory visits.
Price Action: SZLS shares are trading higher by 22.22% at C$0.11 on TSX on the last check Wednesday.
Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
